Omiloxetine

Last updated
Omiloxetine
Omiloxetine.svg
Clinical data
ATC code
  • None
Identifiers
  • 2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C27H25F2NO4
Molar mass 465.497 g·mol−1
3D model (JSmol)
Density 1.3±0.1 g/cm3
Melting point 228.65 °C (443.57 °F)
Boiling point 587.2 °C (1,089.0 °F)
Solubility in water 0.0015 mg/mL (20 °C)
  • Fc1ccc(cc1)C(=O)CN3CC[C@H](c2ccc(F)cc2)[C@H](C3)COc4ccc5OCOc5c4
  • InChI=1S/C27H25F2NO4/c28-21-5-1-18(2-6-21)24-11-12-30(15-25(31)19-3-7-22(29)8-4-19)14-20(24)16-32-23-9-10-26-27(13-23)34-17-33-26/h1-10,13,20,24H,11-12,14-17H2/t20-,24-/m1/s1
  • Key:FAHGZANUNVVDFL-HYBUGGRVSA-N

Omiloxetine (omiloextinum, omiloxetino INN) [1] was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned. [2] [3]

Rafael Foguet also patented Abaperidone.

Related Research Articles

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

<span class="mw-page-title-main">SRI International</span> American scientific research institute (founded 1946)

SRI International (SRI) is a United States-based nonprofit scientific research institute and organization headquartered in Menlo Park, California. It was established in 1946 by trustees of Stanford University to serve as a center of innovation to support economic development in the region.

<span class="mw-page-title-main">Erowid</span> Non-profit educational organization

Erowid, also called Erowid Center, is a non-profit educational organization that provides information about psychoactive plants and chemicals.

<span class="mw-page-title-main">Drug development</span> Process of bringing a new pharmaceutical drug to the market

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery. It includes preclinical research on microorganisms and animals, filing for regulatory status, such as via the United States Food and Drug Administration for an investigational new drug to initiate clinical trials on humans, and may include the step of obtaining regulatory approval with a new drug application to market the drug. The entire process—from concept through preclinical testing in the laboratory to clinical trial development, including Phase I–III trials—to approved vaccine or drug typically takes more than a decade.

The nomenclature of monoclonal antibodies is a naming scheme for assigning generic, or nonproprietary, names to monoclonal antibodies. An antibody is a protein that is produced in B cells and used by the immune system of humans and other vertebrate animals to identify a specific foreign object like a bacterium or a virus. Monoclonal antibodies are those that were produced in identical cells, often artificially, and so share the same target object. They have a wide range of applications including medical uses.

Salvia divinorum, a psychoactive plant, is legal in most countries. Exceptions, countries where there is some form of control, include Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Italy, Japan, South Korea, Norway, Poland, United Kingdom, Ukraine, Spain, Sweden, Vietnam, Armenia and 33 states and territories of the United States.

<span class="mw-page-title-main">Bruker</span> American scientific instrument manufacturer

Bruker Corporation is an American manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis. It is headquartered in Billerica, Massachusetts, and is the publicly traded parent company of Bruker Scientific Instruments and Bruker Energy & Supercon Technologies (BEST) divisions.

<i>Salvia divinorum</i> Species of plant

Salvia divinorum is a species of plant in the sage genus Salvia, known for its transient psychoactive properties when its leaves, or extracts made from the leaves, are administered by smoking, chewing, or drinking. The leaves contain the potent compound salvinorin A and can induce a dissociative state and hallucinations.

<span class="mw-page-title-main">Retigabine</span> Anticonvulsant, which works as a potassium-channel opener

Retigabine (INN) or ezogabine (USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. It was approved by the European Medicines Agency under the trade name Trobalt on March 28, 2011, and by the United States Food and Drug Administration (FDA), under the trade name Potiga, on June 10, 2011. Production was discontinued in June 2017.

<span class="mw-page-title-main">Prinaberel</span> Chemical compound

Prinaberel is a synthetic, nonsteroidal, and highly selective agonist of the ERβ subtype of the estrogen receptor. It is used in scientific research to elucidate the role of the ERβ receptor. Studies have indicated that selective ERβ agonists like prinaberel could be useful in the clinical treatment of a variety of medical conditions including inflammatory bowel disease, rheumatoid arthritis, endometriosis, and sepsis. Accordingly, prinaberel either was or still is under investigation by Wyeth for the treatment of some of these conditions.

Calico Life Sciences LLC is an American biotechnology company with a focus on the biology of aging, attempting to devise interventions that may enable people to lead longer and healthier lives. It is a subsidiary of Alphabet Inc.

<span class="mw-page-title-main">Arbutus Biopharma</span> Canadian Bio Tech Company

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.

References

  1. "Proposed INN: List 76" (PDF). WHO Drug Information. 10 (4): 212–213. 1996.
  2. Terencio J (2005-12-05). "Omiloxetine - Ferrer licensing offer, worldwide". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.
  3. De Lecea C (2003-12-08). "Omiloxetine - Ferrer partnering opportunity, worldwide Ferrer preclinical data". R & D Focus Drug News. Archived from the original on 2016-03-07. Retrieved 2012-05-19.